Creative Medical Technology (NASDAQ:CELZ) is a clinical-stage regenerative medicine company that specializes in the research, development and commercialization of autologous cell-based therapies. The company’s primary focus is on the isolation and application of adipose-derived regenerative cells (ADRCs) to address unmet medical needs in musculoskeletal disorders, orthopedic injuries and wound healing. By leveraging minimally invasive liposuction techniques, Creative Medical Technology enables physicians to harvest a patient’s own fat tissue, process it to concentrate regenerative cells, and deliver them at the point of care for therapeutic applications.
The company offers a suite of proprietary products designed to support the collection, processing and administration of ADRCs. Its key systems include collection kits for adipose tissue aspiration and closed‐system devices that isolate and concentrate regenerative cells in a sterile environment. Creative Medical Technology also provides procedural training and technical support to clinicians, ensuring proper adoption of its technologies in both surgical and outpatient settings. In addition, the company collaborates with research institutions to expand the range of clinical indications for its cell therapy platforms, including potential applications in neuropathy and chronic soft tissue injuries.
Headquartered in Houston, Texas, Creative Medical Technology operates under a comprehensive quality management system to comply with U.S. regulatory requirements. The company conducts clinical activities primarily within the United States and Canada, engaging with orthopedic surgeons, plastic surgeons and interventional specialists. Through strategic partnerships with regional medical centers, it continues to build a clinical evidence base for the safety and efficacy of ADRC therapies, positioning itself to serve a growing market for minimally invasive, regenerative treatments.
Founded in the mid-2000s, Creative Medical Technology has evolved under the leadership of Chairman and Chief Executive Officer Mathew F. Getz, who brings extensive experience in life sciences and medical device commercialization. The executive team also includes seasoned professionals in research, regulatory affairs and operations, guiding the company’s efforts to expand its product pipeline and advance toward broader clinical adoption. As regulatory pathways for cell-based therapies continue to mature, Creative Medical Technology remains focused on innovation in autologous regenerative medicine and on delivering practical solutions to physicians and patients.
